Vivos Therapeutics, Inc. - VVOS STOCK NEWS

Vivos Therapeutics (NASDAQ: VVOS) announced significant findings from a peer-reviewed study on its FDA-registered Vivos Guide, an intraoral device aimed at reducing pediatric tooth decay.

The study, led by Dr. Toshi Hart, demonstrated a 76.4% reduction in tooth decay risk at six months and 57.9% at twelve months for children using the device compared to a control group. The device encourages nasal breathing over mouth breathing, potentially increasing salivary factors that combat tooth decay.

Vivos Therapeutics (NASDAQ: VVOS) has established the Vivos Medical Consortium to enhance research in managing obstructive sleep apnea (OSA). Co-chaired by Dr. Clete Kushida from Stanford and Dr. Cecilia Wu from the University of Alberta, the consortium comprises specialists from various medical fields. The group's goal is to improve physician-dental collaboration and explore new applications for Vivos' OSA technology, which has shown promising results. Vivos aims to facilitate broader adoption of its innovative, non-invasive therapies for patients with OSA.

Vivos Therapeutics, Inc. (NASDAQ: VVOS), a company focused on innovative treatments for sleep-disordered breathing, will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021, at 2:20 pm EST. The presentation will be led by Chairman Kirk Huntsman and CFO Brad Amman. Interested investors can register for a free spectator pass. Vivos offers non-surgical solutions for obstructive sleep apnea through its Vivos System, which has helped over 19,000 patients globally. A replay will be available on their website post-event.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced that CEO Kirk Huntsman will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 am EDT. Investors can register for the event and listen to the presentation via provided links. Vivos specializes in innovative treatments for mild-to-moderate obstructive sleep apnea (OSA), offering solutions like the Vivos System, which has aided over 19,000 patients worldwide. A replay of the presentation will be available on Vivos’ website post-event.

Vivos Therapeutics (NASDAQ: VVOS) has announced a partnership with Empower Sleep to enhance diagnostic and consultation services for obstructive sleep apnea (OSA) patients in North America. This partnership aims to leverage their technologies for improved patient screenings and treatments using Vivos' VivoScore product. Recent data shows that 56% of patients tested by Vivos dentists received positive OSA diagnoses, with 50% entering treatment. The collaboration seeks to increase access to personalized telemedicine care, addressing the needs of patients intolerant to traditional CPAP devices.

Vivos Therapeutics has received FDA 510(k) market clearance for its mmRNA device, a non-invasive treatment for mild to moderate obstructive sleep apnea (OSA). This approval increases the potential for insurance reimbursement, including Medicare. With over 54 million Americans affected by sleep apnea, Vivos aims to provide a cost-effective alternative to current treatments. The company also plans to appeal the FDA's denial of its DNA appliance application, although this is not expected to impact existing operations significantly.

Vivos Therapeutics (NASDAQ: VVOS) has released detailed results from a national study on its FDA Class 1 DNA appliance for sleep-disordered breathing. The data indicates that one in four patients reported complete resolution of obstructive sleep apnea (OSA) symptoms. Among 20 patients with severe OSA, average improvement in AHI scores was 53%, with none reporting worsening symptoms. The average improvement for 18 patients with moderate OSA was 64%. The results highlight the effectiveness of Vivos' treatment protocols compared to traditional methods.

Vivos Therapeutics reported a 37.5% increase in Q2 revenue, reaching $4.5 million, and a 30% rise from Q1 2021. Gross profit for Q2 was $3.6 million, with an 81% gross margin. However, the company faced a net loss of $4.0 million for the quarter, up from <$1.4 million> in Q2 2020. Vivos has treated over 19,000 patients and opened a training center in Denver. New initiatives, including the VivoScore test, have shown a significant increase in sleep apnea testing, indicating expanding market adoption.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Q3 Virtual Investor Summit on August 18, 2021, at 9:30 am EST. The presentation will feature CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew. Vivos focuses on developing innovative treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA). The company’s Vivos System offers a non-invasive, cost-effective solution using customized oral appliances, proven effective in over 19,000 patients globally. Interested investors can register for the presentation online.